Smith & Nephew Snats ((SNN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Smith & Nephew is currently conducting a post-market clinical study titled ‘A Prospective, Multi-center, Post-Market Clinical Study to Evaluate the Safety and Effectiveness of the REFLEX ULTRA 45 for the Coblation Inferior Turbinate Reduction in China.’ The study aims to assess the safety and effectiveness of the REFLEX ULTRA 45 device for treating nasal obstruction due to inferior turbinate hypertrophy. This research is significant as it could enhance treatment options for patients in China.
The intervention being tested is the REFLEX ULTRA 45, a device used for coblation inferior turbinate reduction. It is designed to be used with the COBLATOR II or WEREWOLF controller systems and is intended for single-use surgical procedures.
The study follows an interventional design with a single-group model. There is no masking involved, and the primary purpose is treatment. The study is being conducted across approximately six sites in mainland China, involving 105 subjects.
The study began on June 9, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 9, 2025. These dates are crucial for tracking the progress and potential release of results.
This clinical study update could impact Smith & Nephew’s stock performance positively, as successful results may boost investor confidence and market share in the medical device industry. Competitors in the nasal obstruction treatment market may need to monitor these developments closely.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.